CHRONIC TREATMENT WITH AN ANXIOLYTIC DOSE OF THE 5-HT(1A) AGONIST IPSAPIRONE DOES NOT ALTER IPSAPIRONE ACUTE NEUROENDOCRINE EFFECTS B Schmidt Psychoneuroendocrinology. 1993-01-01; 18(7): 457-466 DOI: 10.1016/0306-4530(93)90039-n Auteurs Bordeaux Neurocampus Francis Chaouloff
